Compare Google Inc (GOOG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Alphabet (GOOG) trades at $349.52, up 0.16% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income margin of 32.8%, supported by 87% analyst buy ratings and a $435.29 consensus price target. Recent news highlights AI infrastructure investments and legal challenges, while cash flow trends show significant operational strength despite rising capital expenditures.

Outlook remains positive with AI-driven growth potential, though risks include regulatory scrutiny and capital expenditure pressures. The stock offers attractive valuation with P/E of 17.24 and strong profitability metrics, positioning it well for long-term investors despite near-term legal headwinds and competitive dynamics in the AI space.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.